Strontium malonate

Strontium malonate is now in FDA clinical trials for the treatment of Osteopenia and Osteoporosis. There could be a new pharmaceutical treatment for Osteopenia and Osteoporosis coming to the market if these FDA trials are successful.

A firm in San Francisco, California named Osteologix, Inc. has applied to the FDA and been accepted for clinical trials of their pharmaceutical form of this drug. This drug, labeled NB S101 for trials, is a dual-acting bone agent, has a demonstrated ability to decrease resorption of bone while maintaining formation of new bone. It is to be taken on as a once-daily tablet.

As early as 1900 researchers knew of strontium, a natural element that is 'next to calcium' on the periodicchart of the elements. The Mayo Clinic used this element successfully in the 1950's but it was not until Servier, a French pharmaceutical firm, was able to synthesize this element so that it could become available as a prescription drug. Currently their drug is sold under the brand name Protelos in the European Union and elsewhere.

In many countries persons with Osteopenia or Osteoporosis use the natural forms of strontium as part of their treatment plan to reverse bone loss. However, some people would like to take a pharmaceutical drug instead of using one of the natural forms of this element.

Strontium malonate may be the answer. Although it is only in phase II trials, there appear few reasons to suppose that the drug will not receive full approval at some time.

To see a press release about these trials go to the Muscloskeletal Report at Strontium Malonate: Osteologix

In July of 2008, an article was published by scientists from the Department of Chemistry at the Technical University of Denmark which showed that:

" After four weeks of treatment with strontium malonate, strontium levels increased from 76 +/- 9 microg g(-1) in placebo-treated dogs to levels of 7.2 +/- 1.7 mg g(-1), 9.5 +/- 2.7 mg g(-1), and 9.8 +/- 2.7 mg g(-1) in groups treated with 300, 1000, and 3000 mg kg(-1) day(-1), respectively.

Strontium induced a highly significant increase in the bone formation marker, bone-specific alkaline phosphatase (BSAP), and an excellent correlation was found with the bone-strontium content. In females, the placebo-treated group showed a decrease in BSAP of 53%, whereas the three strontium malonate-treated groups showed an increase of 60, 276, and 278% for the groups treated with 300, 1000, and 3000 mg kg(-1) day(-1), respectively. For males the corresponding values were -44%, +142%, +194%, and +247% increases in BSAP in the placebo, 300, 1000, and 3000 mg kg(-1) day(-1) groups respectively."

Click here to read information about the many additional Natural Osteopenia treatments that are available at this time.